Eterna Therapeutics (ERNA)
NASDAQ:ERNA
Want to see ERNA full AI Analyst Report?
Total Valuation
Eterna Therapeutics has a market cap or net worth of $13.30M. The enterprise value is -$4.87M.
Market Cap$13.30M
Enterprise Value-$4.87M
Share Statistics
Eterna Therapeutics has 1,166,333 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,166,333
Owned by Insiders23.25%
Owned by Institutions0.03%
Financial Efficiency
Eterna Therapeutics’s return on equity (ROE) is -5.87 and return on invested capital (ROIC) is -316.61%.
Return on Equity (ROE)-5.87
Return on Assets (ROA)-2.41
Return on Invested Capital (ROIC)-316.61%
Return on Capital Employed (ROCE)-3.42
Revenue Per Employee0.00
Profits Per Employee-2.35M
Employee Count6
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Eterna Therapeutics is ―. Eterna Therapeutics’s PEG ratio is -0.01.
PE Ratio―
PS Ratio0.00
PB Ratio3.15
Price to Fair Value3.15
Price to FCF-1.07
Price to Operating Cash Flow-1.37
PEG Ratio-0.01
Income Statement
In the last 12 months, Eterna Therapeutics had revenue of 0.00 and earned -14.08M in profits. Earnings per share was -56.00.
Revenue0.00
Gross Profit0.00
Operating Income-9.32M
Pretax Income-14.13M
Net Income-14.08M
EBITDA-13.84M
Earnings Per Share (EPS)-56.00
Cash Flow
In the last 12 months, operating cash flow was -7.22M and capital expenditures -39.00K, giving a free cash flow of -7.25M billion.
Operating Cash Flow-7.22M
Free Cash Flow-7.25M
Free Cash Flow per Share-6.22
Dividends & Yields
Eterna Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.88
52-Week Price Change-85.45%
50-Day Moving Average6.52
200-Day Moving Average23.69
Relative Strength Index (RSI)65.18
Average Volume (3m)147.10K
Important Dates
Eterna Therapeutics upcoming earnings date is Apr 14, 2023, TBA (Confirmed).
Last Earnings DateNov 8, 2022
Next Earnings DateApr 14, 2023
Ex-Dividend Date―
Financial Position
Eterna Therapeutics as a current ratio of 1.01, with Debt / Equity ratio of 5.67%
Current Ratio1.01
Quick Ratio1.01
Debt to Market Cap0.03
Net Debt to EBITDA0.10
Interest Coverage Ratio-345.15
Taxes
In the past 12 months, Eterna Therapeutics has paid -45.00K in taxes.
Income Tax-45.00K
Effective Tax Rate<0.01
Enterprise Valuation
Eterna Therapeutics EV to EBITDA ratio is -0.45, with an EV/FCF ratio of -0.88.
EV to Sales0.00
EV to EBITDA-0.45
EV to Free Cash Flow-0.88
EV to Operating Cash Flow-0.88
Balance Sheet
Eterna Therapeutics has $9.18M in cash and marketable securities with $389.00K in debt, giving a net cash position of $8.79M billion.
Cash & Marketable Securities$9.18M
Total Debt$389.00K
Net Cash$8.79M
Net Cash Per Share$7.53
Tangible Book Value Per Share$1.42
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Eterna Therapeutics is $30.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$30.00
Price Target Upside14185.71% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-100.00%
EPS Growth Forecast98.68%